CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Unigene Laboratories, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Unigene Laboratories, Inc.
81 Fulton Street
Phone: (973) 265-1100p:973 265-1100 Boonton, NJ  07005-1909  United States Fax: (302) 655-5049f:302 655-5049
This company is no longer actively traded on any major stock exchange.
Business Summary
UNIGENE LABORATORIES, INC.,is a biopharmaceutical company. The Company focuses on the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has three operating locations: administrative and regulatory offices in Boonton, New Jersey; a laboratory researches facility in Fairfield, New Jersey, and a pharmaceutical production facility in Boonton, New Jersey. Initially the Company’s was focused on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications. The Company's first product to market is Fortical, a nasal calcitonin product, received approval from the United States Food and Drug Administration in 2005. It is marketed in the United States by Upsher-Smith Laboratories, Inc., for the treatment of postmenopausal osteoporosis. The Company’s product other than Fortical, will require clinical trials and approvals from regulatory agencies.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201312/31/2012YesYesYes--

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Richard N.Levy 40 3/17/2010 3/17/2010
Chief Executive Officer, Director AshleighPalmer 49 9/5/2012 6/9/2010
Chief Financial Officer BrianZietsman 48 8/13/2012 4/9/2012
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 53 (As of 2/28/2013)
Outstanding Shares: 95,978,952 (As of 3/31/2013)
Shareholders: 462
Stock Exchange: OTC
Federal Tax Id: 222328609
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023